|
1. |
Rapid Development of Subacute Myelopathy in Three Organ Transplant Recipients after Transmission of Human T-Cell Lymphotropic Virus Type I from a Single Donor. |
|
Transplantation,
Volume 75,
Issue 1,
2003,
Page 1-2
H. Osman, Consultant Virologist,
Preview
|
PDF (92KB)
|
|
ISSN:0041-1337
出版商:OVID
年代:2003
数据来源: OVID
|
2. |
Expression of A20 in the vessel wall of rat-kidney allografts correlates with protection from transplant arteriosclerosis |
|
Transplantation,
Volume 75,
Issue 1,
2003,
Page 3-9
Uta Kunter,
Jürgen Floege,
Almut von Jürgensonn,
Tomislav Stojanovic,
Saskia Merkel,
Hermann Gröne,
Christiane Ferran,
Preview
|
PDF (701KB)
|
|
摘要:
Background.Chronic rejection with development of transplant arteriosclerosis is the major culprit involved in loss of kidney allografts. The allografts’ fate was thought to depend on the intensity of the host immune responses and the potency of immunosuppressive regimens. Recent data suggests that grafts contribute to their own survival by way of up-regulation of “cytoprotective” genes.Methods.We analyzed the expression of four cytoprotective genes, A20, Bcl-2, Bcl-xLand heme oxygenase (HO)-1, in three rat renal allograft models of chronic rejection: Fisher 344–Lewis (F344/Lew), Dark Agouti–Brown Norway (DA/BN), and DA–Wistar-Furth (WF). We chose these genes for their known anti-inflammatory and anti-apoptotic function in endothelial cells (EC) and the atheroprotective function of A20 in smooth muscle cells (SMC).Results.Twenty-eight and 9 weeks following transplantation, F344/Lew and DA/BN transplants had stable graft function. Histopathologic analysis showed moderate tissue damage, minimal cellular infiltrates, and preserved vascular integrity correlating with high expression of A20 in SMC. Conversely, impaired allograft function in the DA/WF combination with substantial transplant arteriosclerosis was noted in 60% of the grafts correlating with absent or decreased A20 expression in EC and SMC. In all combinations, expression of HO-1, Bcl-2, and Bcl-xLcolocalized with infiltrating cells and was not informative on the graft status.Conclusions.We demonstrate for the first time a strict correlation between A20 expression in the vessel and the absence of transplant arteriosclerosis in rat kidney-allograft models. This data is similar to data obtained in human kidney allografts and suggests that A20 may represent a novel therapeutic target for the prevention of chronic allograft rejection.
ISSN:0041-1337
出版商:OVID
年代:2003
数据来源: OVID
|
3. |
Improvement in human decay accelerating factor transgenic porcine kidney xenograft rejection with intravenous administration of gas914, a polymeric form of &agr;gal1 |
|
Transplantation,
Volume 75,
Issue 1,
2003,
Page 10-19
Robert Zhong,
Yigang Luo,
Hongji Yang,
Bertha Garcia,
Anand Ghanekar,
Patrick Luke,
Subrata Chakrabarti,
Ginette Lajoie,
M. Phillips,
Andreas Katopodis,
Rudolf Duthaler,
Mark Cattral,
William Wall,
Anthony Jevnikar,
Michele Bailey,
Gary Levy,
David Grant,
Preview
|
PDF (2404KB)
|
|
摘要:
Background.The present study was undertaken to determine whether intravenous administration of GAS914, a polymeric form of &agr;Gal, would minimize porcine kidney xenograft rejection in baboons. Human decay accelerating factor renal xenografts were transplanted into 16 baboon recipients.Methods.Baseline immunosuppression for all groups included cyclosporine A, cyclophosphamide, SDZ-RAD, and methylprednisolone. Group 1 received only baseline immunosuppression; group 2 animals received low-dose GAS914 with baseline immunosuppression; group 3 animals received high dose GAS914 with high-dose baseline immunosuppression; and animals from group 4 received high-dose GAS914 and low-dose baseline immunosuppression.Results.None of the animals in this study developed hyperacute rejection. Intravenous administration of GAS914 significantly reduced xenoreactive antibodies as measured by antiporcine hemolytic assays and anti-Gal (immunoglobulin [Ig] G and IgM) antibody assays. Rejection was less severe in the GAS914-treated group. Only 25% (3 of 12) of GAS914-treated animals were killed as a result of rejection, whereas 75% (three of four) of non–GAS914-treated animals were killed because of terminal rejection (P<0.01). Protocol biopsies demonstrated that the degree of acute humoral xenograft rejection (AHXR) was reduced in the GAS914-treated animals compared with non–GAS914-treated animals.Conclusion.The intravenous administration of GAS914 reduces xenoreactive antibody levels and reduces the degree of porcine kidney xenograft rejection, but does not improve survival. AHXR and drug toxicity remain major barriers to the long-term success of xenotransplantation.
ISSN:0041-1337
出版商:OVID
年代:2003
数据来源: OVID
|
4. |
Preconditioning with cyclosporine a or fk506 differentially regulates mitogen-activated protein kinase expression in rat kidneys with ischemia/reperfusion injury12 |
|
Transplantation,
Volume 75,
Issue 1,
2003,
Page 20-24
Chul Woo Yang,
Hee Jong Ahn,
Ju Young Jung,
Wan Young Kim,
Can Li,
Bum Soon Choi,
Hyung Wook Kim,
Yong Soo Kim,
In Sung Moon,
Jin Kim,
Byung Kee Bang,
Preview
|
PDF (829KB)
|
|
摘要:
Background.The signaling pathways of mitogen-activated protein kinases (MAPKs) are important molecular components responsible for ischemia/reperfusion (I/R) injury in the kidneys. Preconditioning with cyclosporine A (CsA) or FK506 reduces subsequent I/R injury. We studied the effect of preconditioning with CsA or FK506 on MAPK expression in ischemic rat kidneys.Methods.Two separate studies were performed using Sprague-Dawley rats. First, MAPK (extracellular signal-regulated kinase [ERK], jun N-terminal kinase [JNK], p38) expressions were observed at 0, 10, 20, 30, 60, 120, and 1,440 min after I/R injury. Second, the effects of preconditioning with CsA or FK506 on MAPK expressions were observed in rat kidneys with I/R injury. I/R injury was induced by clamping both renal arteries for 45 min. Rats were pretreated with intravenous (IV) CsA (3 mg/kg) or IV FK506 (0.3 mg/kg) 6 hr before I/R injury and killed 30 min later. Expression of MAPK was measured using immunoblot and immunohistochemistry.Results.MAPK (ERK, JNK, p38) expressions were significantly increased in kidneys with I/R injury compared with sham-operated controls, and immunohistochemistry revealed increased MAPK immunoreactivity in renal tubules of the outer medulla. Kidneys preconditioned with low-dose CsA or FK506 showed significantly increased ERK expression compared with kidneys with I/R injury alone (CsA, 9.5- vs. 4.5-fold; FK506 10.4- vs. 4.5-fold:P<0.05) but showed decreased JNK (CsA, 3.8- vs. 5.3-fold; FK506, 3.4- vs. 5.3-fold:P<0.05) and p38 expression (CsA, 2.5- vs. 3.7-fold; FK506, 2.1- vs. 3.7-fold:P<0.05).Conclusions.Preconditioning with CsA or FK506 differentially regulates the expression of MAPK in rat kidneys with I/R injury, and this may explain the remarkable protective effects of these agents.
ISSN:0041-1337
出版商:OVID
年代:2003
数据来源: OVID
|
5. |
Split tolerance to a composite tissue allograft in a swine model |
|
Transplantation,
Volume 75,
Issue 1,
2003,
Page 25-31
David Mathes,
Mark Randolph,
Mario Solari,
Jamal Nazzal,
G. Nielsen,
J. Arn,
David Sachs,
W. P. Lee,
Preview
|
PDF (4117KB)
|
|
摘要:
Background.The antigenicity of skin is a major obstacle to expanding human composite tissue transplantation. For example, multiple rejection episodes of the skin have been noted in clinical hand transplant patients. We have previously demonstrated tolerance to vascularized musculoskeletal allografts in major histocompatibility complex (MHC)-matched miniature swine treated with 12 days of cyclosporine. This regimen did not reproducibly lead to tolerance to subsequent frozen donor skin grafts. However, such skin grafts did not have a primary vascular supply. The aim of this study was to determine if tolerance to limb allografts with a vascularized skin component could be achieved with MHC matching and a 12-day course of immunosuppression.Methods.Hind limb grafts harvested with a 100 cm2cutaneous paddle were transplanted heterotopically into six MHC-matched, minor antigen-mismatched miniature swine. All animals received a 12-day course of cyclosporine. One control animal was not immunosuppressed. Grafts were evaluated with biweekly biopsies and tissue viability determined by histologic analysis. To test for sensitization, frozen donor skin grafts were applied to all animals that survived to postoperative day 100.Results.All treated animals (n=6) were tolerant to their musculoskeletal allografts at the time of necropsy (>100 days) regardless of the status of the epidermis. One animal demonstrated tolerance to the skin for more than 180 days. The other five animals demonstrated prolonged survival of the epidermal portion of the graft. The control animal rejected the graft epidermis at 10 days postoperatively. Frozen donor skin grafts demonstrated accelerated rejection (<10 days) in three of the animals and led to simultaneous rejection of both the epidermis of the allograft and the skin graft in the long-term tolerant animal. The rejection of the skin grafts did not break tolerance to the musculoskeletal portion in any of the animals.Conclusions.All animals exhibited indefinite survival of the musculoskeletal portion of their allografts but only prolonged survival of the epidermis. The loss of the graft skin appears to be the result of an isolated immune reaction to the skin, and, in particular, the epidermis. This observation is further substantiated by the accelerated rejection of secondarily placed frozen donor skin grafts.
ISSN:0041-1337
出版商:OVID
年代:2003
数据来源: OVID
|
6. |
Induction of tolerance to hind limb allografts in rats receiving cyclosporine A and antilymphocyte serum: effect of duration of the treatment |
|
Transplantation,
Volume 75,
Issue 1,
2003,
Page 31-36
Kagan Ozer,
Ramadan Oke,
Raffi Gurunluoglu,
Maciej Zielinski,
Dariusz Izycki,
Rita Prajapati,
Maria Siemionow,
Preview
|
PDF (483KB)
|
|
摘要:
Background.This study assessed the ability of antilymphocyte serum (ALS) and cyclosporine A (CsA) to induce tolerance for hind limb composite tissue allograft in rats without chronic immunosuppression.Methods.Hind limb transplantations were performed in Lewis-Brown-Norway (LBN, RT1l+n) and Lewis (LEW, RT1l) rats. Treatment consisted of ALS only (0.4 mL/kg), CsA only (16 mg/kg), and a combination of CsA and ALS, and it was administered 12 hr before surgery at three different intervals (7, 14, and 21 days). Long-term survivors were tested for tolerance by standard skin grafting from the recipient (LEW), the donor (LBN), and the third party (ACI, RT1a) 60 days after cessation of the treatment and by mixed lymphocyte reaction at 100 days. T-cell lines were analyzed with flow cytometry.Results.Single use of ALS in all treatment intervals did not prolong allograft survival. Single use of CsA extended survival up to 23 days in the 21-day protocol group. CsA and ALS caused indefinite survival in two of six rats in the 14-day protocol and in all six rats in the 21-day protocol (>420 days). The six long-term survivors in the 21-day protocol accepted the skin grafts from the donor (LBN) and the recipient (LEW) and rejected third-party grafts (ACI). Tolerant animals showed a donor-specific hematopoietic chimerism of 35% to 42% in the peripheral blood. Mixed lymphocyte reaction assay demonstrated tolerance to the host and donor alloantigens and increased response to the third party.Conclusions.Administration of CsA and ALS for 21 days induced donor-specific tolerance in the recipients of the rat hind limb composite tissue allografts. The mechanism of tolerance should be investigated further.
ISSN:0041-1337
出版商:OVID
年代:2003
数据来源: OVID
|
7. |
Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation12 |
|
Transplantation,
Volume 75,
Issue 1,
2003,
Page 37-43
Joseph Lawen,
Elizabeth Davies,
Georges Mourad,
Frederic Oppenheimer,
Miguel Molina,
Lionel Rostaing,
Alan Wilkinson,
Laura Mulloy,
Bernard Bourbigot,
Hans Prestele,
Alexander Korn,
Danièle Girault,
Preview
|
PDF (1251KB)
|
|
摘要:
Background.Acute rejection remains a major problem in renal transplantation. Immunoprophylaxis with basiliximab (Simulect) has achieved significant reductions in acute rejection episodes in renal allograft recipients receiving dual immunosuppression. This study explored the tolerability and cumulative benefit of combining basiliximab with triple-drug therapy—cyclosporine (USP Modified, Neoral), mycophenolate mofetil, and steroids.Methods.In a randomized, double-blind, placebo-controlled, multicenter study, 123 kidney transplant recipients received either basiliximab at 20 mg before transplantation (day 0) and 20 mg on day 4 (n=59), or placebo (n=64). All received triple-drug immunosuppression and were followed for 6 months.Results.Tolerability of basiliximab was equivalent to placebo, with no increase in serious adverse events, infection, malignancy, or posttransplant lymphoproliferative disorder. At 6 months, there were trends in favor of basiliximab over placebo in the incidences of first biopsy-confirmed acute rejection (15.3% vs. 26.6%,P=NS) and of acute rejection treated with antibody (5.1% vs. 15.6%,P=NS). Kaplan-Meier estimates at 4 weeks and 6 months were significantly in favor of basiliximab treatment for first acute rejection, biopsy-confirmed rejection, rejection episodes treated with antibody therapy, and treatment failure. Renal function improved more rapidly in the basiliximab group, with mean creatinine clearance at week 2 being 54.7 mL/min versus 43.2 mL/min for placebo (P=0.034). At 12 months, patient survival was 100% in both groups; graft survival was 94.9% with basiliximab and 92.2% with placebo.Conclusions.Basiliximab immunoprophylaxis is safe, well tolerated, and shows a trend toward reduction in number of acute rejection episodes in renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
ISSN:0041-1337
出版商:OVID
年代:2003
数据来源: OVID
|
8. |
Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities |
|
Transplantation,
Volume 75,
Issue 1,
2003,
Page 43-49
Rui Pei,
Jar-how Lee,
Neng-Jen Shih,
Mike Chen,
Paul Terasaki,
Preview
|
PDF (720KB)
|
|
摘要:
Background.It is difficult to assign antibody specificity for highly sensitized patients using a cell panel with multiple antigens per reaction. We describe here a single antigen bead panel for accurate identification of human leukocyte antigen (HLA) antibody specificities by flow cytometry.Methods.A total of 110 single recombinant HLAs, including 34 A locus alleles, 57 B locus alleles, and 19 C locus alleles, were produced by a mammalian expression system. These single antigens were coated onto eight different colored microbeads, which were mixed together in one tube for simultaneous detection of HLA antibodies against eight different antigens per flow cytometry test.Results.Single HLA reacted specifically with the serologically defined monoclonal antibodies. The single antigen panel provided higher resolution than the regular cell panel for antibody detection by uncovering the masked specificities. Single antigens also provided higher sensitivity than the multiple antigens coated onto beads for HLA antibody detection as demonstrated by serum dilution studies. In 10 sera from patients who had rejected a kidney transplant, single antigen beads identified antibodies to 31 of 35 antigens that were mismatched in the donor. Most important, none of the reactions were against antigens present in the recipient.Conclusion.An accurate and sensitive HLA antibody detection method is described using flow cytometry beads coated with single HLAs produced by recombinant technology. The single antigen beads should be useful in predicting negative crossmatch in highly sensitized organ recipients and highly sensitized patients requiring platelets.
ISSN:0041-1337
出版商:OVID
年代:2003
数据来源: OVID
|
9. |
Bone mineral density changes within six months of renal transplantation |
|
Transplantation,
Volume 75,
Issue 1,
2003,
Page 49-54
Ted Mikuls,
Bruce Julian,
Al Bartolucci,
Kenneth Saag,
Preview
|
PDF (241KB)
|
|
摘要:
Background.The effective use of new steroid-sparing immunosuppressive regimens may lower cumulative glucocorticoid use among renal transplant recipients. However, it is unknown what effect this therapeutic trend has had on bone disease.Methods.Unselected newly transplanted inpatients (n=45) were identified and comprehensively evaluated for metabolic bone disease at a median of 16 days (range 9–33) posttransplant. A follow-up evaluation was conducted a median of 5.7 months (range 4.8–9.3) later. Follow-up values for bone mineral density (BMD) and select laboratories were compared with baseline values using nonparametric statistics. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to describe the associations of baseline characteristics, select laboratory values, and cumulative prednisone and cyclosporine use with spinal BMD loss and were calculated using logistic regression.Results.A significant decrease in intact parathyroid hormone (P<0.001) and a significant increase in calcitriol (P=0.02) were noted postengraftment. At follow-up, subjects had lost a mean of 2.4% BMD at the lumbar spine (P=0.003) but did not experience significant declines at the femoral neck. The highest tertiles of cumulative prednisone (OR=28.4; 95% CI 2.5–329 and OR=15.8; 95% CI 1.4–179, respectively) and past alcohol use (OR=9.3; 95% CI 1.46–58.5) were significantly associated with spinal BMD loss.Conclusions.Significant loss in lumbar BMD occurred within 6 months of transplantation in more than one third of a prospective cohort of renal transplant recipients. Lumbar bone loss seemed to be mediated primarily by glucocorticoid dose and a history of alcohol use.
ISSN:0041-1337
出版商:OVID
年代:2003
数据来源: OVID
|
10. |
Combination therapy of mycophenolate mofetil and rapamycin in prevention of chronic renal allograft rejection in the rat1 |
|
Transplantation,
Volume 75,
Issue 1,
2003,
Page 54-59
E. Jolicoeur,
Shijie Qi,
Dasheng Xu,
Louis Dumont,
Pierre Daloze,
Huifang Chen,
Preview
|
PDF (241KB)
|
|
摘要:
Background.Chronic rejection is the leading cause of long-term allograft loss. Until now, no therapy has been recognized as being efficient in its prevention. In addition to their immunosuppressive activity, mycophenolate mofetil (MMF) and rapamycin (RAPA) show diverse properties against vascular smooth muscle cell activity, cell-adhesion molecule expression, and ischemia-reperfusion injury. The combination effect of MMF and RAPA was tested to prevent chronic renal allograft rejection in the rat in this study.Methods.Nephrectomized Lewis recipients underwent orthotopic transplantation with Fisher (F344) kidneys (allograft groups) or Lewis kidneys (isograft control). The initial episode of acute rejection was controlled with a short course of cyclosporine A (CsA) (1.5 mg/kg/day for 10 days). From weeks 4 to 20, animals were thereafter treated every other day either with vehicle, MMF (20 mg/kg), RAPA (0.8 mg/kg), or MMF (20 mg/kg) plus RAPA (0.8 mg/kg) in combination. Animals were sequentially killed at serial intervals over a follow-up of 50 weeks, and histologic study was performed on harvested kidneys according to the Banff working classification for allograft pathology.Results.Animals treated with MMF or RAPA alone showed a Banff sum score similar to the allograft control group (6.31±1.01 and 7.27±1.14 vs. 7.21±1.14, respectively;P>0.05). When the recipient rats were treated with MMF and RAPA in combination, it resulted in a clinically and statistically significant reduction of Banff sum score (4.21±0.79,P<0.01), with specific inhibition of vascular fibrous intimal thickening, allograft glomerulopathy, and interstitial fibrosis.Conclusion.Over a 50-week study, concomitant therapy of MMF and RAPA prevents chronic renal allograft rejection, probably through reduction of ischemic and cytotoxic degenerative changes. These results warrant further investigation in the combination of MMF and RAPA as anti–chronic rejection therapy in clinical transplantation.
ISSN:0041-1337
出版商:OVID
年代:2003
数据来源: OVID
|
|